



Published in final edited form as:

*Adv Biol Regul.* 2013 January ; 53(1): 77–85. doi:10.1016/j.jbior.2012.10.003.

## Characterization of the role of Fhit in suppression of DNA damage

Joshua C. Saldivar<sup>1,2</sup>, Jessica Bene<sup>2</sup>, Seyed Ali Hosseini<sup>2</sup>, Satoshi Miuma<sup>2,3</sup>, Susan Horton<sup>4</sup>, Nyla Heerema<sup>4</sup>, and Kay Huebner<sup>2,\*</sup>

<sup>1</sup>Biomedical Sciences Graduate Program, Ohio State University, Columbus, OH 43210, USA

<sup>2</sup>Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA

<sup>4</sup>Department of Pathology, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

### Abstract

The fragile histidine triad protein, Fhit, has a number of reported tumor suppressive functions which include signaling of apoptosis in cancer cells *in vitro* and *in vivo*, modulation of the DNA damage response, down-regulation of target oncogene expression, suppression of tumor growth *in vivo*, and suppression of cancer cell invasion and metastasis. Most of these functions of Fhit have been observed on exogenous re-expression of Fhit in Fhit-negative cancer cells. However, little is known about the tumorigenic changes that occur in normal or precancerous cells following loss of Fhit expression. Recently, we have shown that shortly after loss of Fhit expression, cells exhibit signs of DNA replication stress-induced DNA damage and develop genomic instability. Here, we extend these findings through investigation of different factors that affect Fhit function to prevent DNA damage. We found that Fhit activity is dependent upon a functional HIT domain and the tyrosine-114 residue, previously shown to be required for tumor suppression by Fhit. Furthermore, Fhit function was shown to be independent of exogenous and endogenous sources of oxidative stress. Finally, Fhit function was shown to be dependent upon Chk1 kinase activity, but independent of Atr or Atm kinases. Evidence suggests that Fhit and Chk1 kinase cooperate to prevent replication stress-induced DNA damage. These findings provide important and unexpected insights into the mechanism whereby loss of Fhit expression contributes to cell transformation.

### Introduction

Genomic instability is an important characteristic of cancer as it enables cells, through increases in mutation frequency, to acquire the numerous phenotypes that contribute to development of the malignant state (Hanahan and Weinberg, 2011). There are various types of genomic instability, but the most commonly observed form in cancer cells is

© 2012 Elsevier Ltd. All rights reserved.

\*Corresponding author: Kay Huebner, PhD, The Biomedical Research Tower, Rm 916, 460 W 12th Ave., Columbus, OH 43210, Ph: 614-292-4850, Fax: 614-688-8675, kay.huebner@osumc.edu.

<sup>3</sup>Present address: Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

chromosomal instability. In precancerous cells, chromosomal aberrations are first detected at common fragile sites, with fragile sites FRA3B and FRA16D being the most frequently affected loci (Tsantoulis et al., 2008). Because these fragile sites are exquisitely sensitive to replicative stress, it is thought that genomic instability originates in precancerous cells because of an increase in DNA replication stress (Gorgoulis et al., 2005; Di Micco et al., 2006). In support of this hypothesis, exposure to chemical agents that cause replication stress generates the same pattern of micro-deletions within FRA3B that is observed in transformed and tumor cells *in vitro* (Durkin et al., 2008). In later stages of cancer development, genomic instability spreads throughout the genome primarily due to a combination of factors including telomere shortening, oxidative stress and defective DNA damage response (Negrini et al., 2010).

Notably, FRA3B and FRA16D reside within the FHIT and WWOX genes, respectively, and deletions within FHIT and WWOX are common in tumor cells and can lead to reduction or loss of Fhit and Wwox protein expression (Durkin and Glover, 2007; Guler et al., 2005). It has been estimated that FHIT is the most frequently altered gene in cancer, rivaling the TP53 gene. In addition to the frequency and clonal pattern of genetic alterations at the FHIT locus in cancer cells, there is considerable phenotypic evidence that Fhit is a *bona fide* tumor suppressor. First, Fhit knockout mice develop more spontaneous tumors and dramatically more carcinogen-induced tumors than wild-type littermates (Zanesi et al., 2001), and viral-mediated FHIT gene delivery prevents and can even cause regression of carcinogen-induced tumors (Ji et al., 1999; Ishii et al., 2001; Dumon et al., 2001). Secondly, over-expression of Fhit in Fhit-negative cancer cell lines suppresses tumorigenicity of xenografts in mice (Siprashvili et al., 1997; Roz et al., 2002; Sevignani et al., 2003). Mechanistically, Fhit suppresses tumor formation by activating apoptotic pathways and down-regulating expression of target oncogenes. In response to oxidative stress, Fhit interacts with ferrodoxin reductase in mitochondria to enhance reactive oxygen species production followed by caspase-3 activation and apoptosis (Trapasso et al., 2008; Pichiorri et al., 2009; Okumura et al., 2009). In response to genotoxic stress, Fhit modulates the DNA damage response such that cancer cells commit to apoptosis (Saldivar et al., 2010). There is also evidence that Fhit can affect calcium release from mitochondria and thereby promote apoptosis (Rimessi et al., 2009). Finally, Fhit has been shown to negatively regulate the epithelial-to-mesenchymal transition and to minimize the invasiveness and metastatic potential of cancer cells (Jayachandran et al., 2007; Joannes et al., 2010).

Because of reports that Fhit-negative cells have altered DNA damage responses, increased survival following genotoxic insult and a higher frequency of mutations, Fhit has been called the guardian of the preneoplastic genome, acting to eliminate genetically-altered cells through apoptosis and thereby guard against tumorigenic changes (Pichiorri et al., 2008). However, Fhit has recently been shown to have a more direct role in maintaining genomic stability (Saldivar et al., 2012). In this study, it was shown that upon loss of Fhit expression, cells are unable to efficiently replicate DNA due to a failure to adequately synthesize thymidine triphosphate pools. As a result, Fhit-deficient cells accumulate stalled replication forks and spontaneous DNA double-strand breaks (DSBs) culminating in chromosome aberrations and acquisition of cancerous phenotypes. Examples of the chromosome alterations developed following Fhit loss include chromosome breaks and gaps, sister-chromatid exchanges, and changes in chromosome number (for examples, Fig. 1). From these findings, an attractive model for the initiation of genomic instability in preneoplastic cells through loss of Fhit expression was proposed (Saldivar et al., 2012). We now further characterize the cellular processes through which Fhit suppresses the formation of spontaneous DNA damage.

## Materials and methods

### Cell lines and reagents

HEK293, H1299 and kidney epithelial cells established from wild-type and Fhit knockout C57Bl/B6 mice were cultured in MEM medium supplemented with 10% FBS and 100 µg/ml gentamicin. Cells were treated for 4 h with the Chk1 inhibitor, SB218078, at a final concentration of 2 µM. Cells were treated for 4 h with the ATR inhibitor, ATR-45, at a final concentration of 10 µM. Cells were treated with N-acetyl-L-cysteine (NAC) at a final concentration of 3 mM.

### Plasmids and siRNA transfections

siRNAs were transfected into HEK293 cells as previously described (Saldivar et al., 2012). In brief, 1 µg of Fhit siRNA or control siRNA was mixed with 5 µl of Lipofectamine (Invitrogen) and diluted in Opti-MEM (Gibco) and added to cells. Two days following transfections, Fhit expression was assessed to confirm knockdown. RcCMV-Flag plasmids with Fhit wild-type cDNA, Fhit-H96N mutant cDNA or Fhit-Y114A mutant cDNA were transfected in H1299 cells using Lipofectamine 2000 (Invitrogen) according to the protocol provided by the manufacturer.

### Comet assays

Neutral comet assays were performed using the CometAssay kit (Trevigen) as previously described (Saldivar et al., 2012).

## Results and discussion

### The Fhit-substrate complex

Fhit is a member of the HIT family of nucleoside hydrolases and transferases. Specifically, Fhit catalyzes hydrolysis of two dinucleosides, diadenosine triphosphate and diadenosine tetraphosphate, *in vitro* (Barnes et al., 1996), though the *in vivo* substrate relevant to Fhit biological functions is not known. Fhit mutants that are unable to bind candidate dinucleoside substrates in *in vitro* biochemical assays, are unable to participate in known *in vivo* Fhit functions, such as apoptosis, binding to chaperones for transport to mitochondria and interaction with mitochondrial ferredoxin reductase to modulate production of reactive oxygen species (Pichiorri et al., 2009). Furthermore, these Fhit mutants fail to suppress tumor growth in mice or cause apoptosis in tumor cells *in vitro* (Siprashvili et al., 1997; Trapasso et al., 2003). To determine if prevention of DSBs by Fhit is also dependent upon enzymatic or substrate-binding activity of Fhit, we transiently transfected Fhit-negative H1299 cells with pRcCMV plasmids for expression of wild type (wt) Fhit, a His96Asn Fhit mutant (H96N) with increased substrate binding and decreased catalytic activity, or a Tyr114Ala mutant (Y114A) with very poor substrate-binding affinity (Trapasso et al., 2003; Pichiorri et al., 2009). Immunoblotting and indirect immunofluorescence confirmed expression and equivalent transfection efficiencies for all plasmid transfections (Fig. 2A–C). To measure DSBs we performed neutral comet assays on the transfected H1299 cells and measured the comet tail moment of individual cells, an indirect measurement of the degree of DNA DSBs. The results revealed that the Y114A mutant was completely unable to suppress spontaneous DNA breaks compared to the empty vector control (Fig. 2D), while the H96N mutant reduced DSBs to a level intermediate between wt Fhit and empty vector control. Similar results were obtained in Fhit-negative MKN74 stomach cancer cells with stable expression of Fhit wt, H96N mutant, or the empty vector control. Thus, as is the case with Fhit and Fdxx interaction, induction of apoptosis and tumor suppression, a Fhit-substrate complex participates in preventing spontaneous DNA damage.

Interestingly, other members of the HIT family of nucleotide hydrolases and transferases, including Aprataxin and Hint1, have reported roles in DNA repair (Martin et al., 2011). Aprataxin is encoded by the APTX gene, which is mutated in patients with the neurological disorder, ataxia-ocular apraxia (Date et al., 2001; Moreira et al., 2001). Aprataxin associates with DNA repair proteins XRCC1 and PARP-1 (Sano et al., 2004; Gueven et al., 2004) and removes abortive DNA ligation intermediates, allowing ligation and repair of ssDNA nicks and gaps (Ahel et al., 2006). Hint1 reportedly participates in repair of DSBs, through interaction with and modulation of  $\gamma$ H2AX and ATM signaling in response to ionizing radiation-induced DSBs (Li et al., 2008). HIT proteins have apparently evolved functions necessary for maintaining genomic integrity, and thus, the Fhit-substrate complex may participate in an important reaction to promote DNA replication progression. In accord with this hypothesis, a mutant of Hnt2, the Fhit homolog in *Saccharomyces cerevisiae*, interacts negatively with mutants of multiple genes involved in response to DNA damage and replication, including Pol3, the catalytic subunit of DNA polymerase  $\delta$  (Constanzo et al., 2010).

### Exogenous and endogenous oxidative stress

Oxidative stress can cause DNA damage, most notably the oxidation of guanine to form 8-oxo-2'-deoxyguanosine (Cooke et al., 2003; Evans et al., 2004), and reducing the reactive oxygen species (ROS) burden on a cell prevents accumulation of DSBs (Sung et al., 2010). Fhit is known to regulate ROS production in response to oxidative stress through interaction with Fdxr in mitochondria. We investigated whether Fhit-deficient cells develop DSBs because of increased DNA oxidation. First, we cultured kidney epithelial cells established from Fhit<sup>+/+</sup> or Fhit<sup>-/-</sup> mice in the presence or absence of N-acetyl-L-cysteine (NAC), an antioxidant, for 40 h and measured DNA breaks with the neutral comet assay. While NAC treatment reduced DNA damage in Fhit<sup>+/+</sup> cells, it had no effect on Fhit<sup>-/-</sup> cells (Fig. 3A), suggesting that Fhit does not protect against DNA damage caused by endogenous ROS. Next, we cultured Fhit<sup>+/+</sup> or Fhit<sup>-/-</sup> epithelial cells in normal atmospheric conditions (20% O<sub>2</sub>) or in a low oxygen environment (5% O<sub>2</sub>) closer to physiological oxygen levels. After 48 h, the degree of DSBs was evaluated using the neutral comet assay. We observed no difference in the spontaneous DSBs when cells were grown in the low oxygen environment compared to the normal growth conditions (Fig. 3B). We conclude that the spontaneous DSBs in Fhit-deficient cells are not caused by an increase in oxidative stress.

### Fhit and the DNA damage checkpoint kinases

In response to DNA damage, cells activate an elaborate response to arrest cell cycle progression, signal repair and choose whether to restart cell proliferation, remain in a state of senescence, or commit to apoptosis (Branzei and Foiani, 2009). This response is collectively referred to as the DNA damage response (DDR). Central to the DDR are the checkpoint kinases ATM, ATR and Chk1. Chk1 is a checkpoint kinase that responds to fork stalling during S/G2 phase during replication. It regulates cell-cycle checkpoint to arrest cells in S and G2 phases (Dai and Grant, 2010). ATR plays a role at stalled forks and double strand breaks by activating Chk1 via phosphorylating Chk1 (Guo et al., 2000; Liu et al., 2000; Cimprich and Cortez, 2008). ATM also acts by phosphorylating multiple targets in response to DSBs (Lavin, 2008). While these 3 kinases have overlapping roles, they also perform separate specific functions.

Knowing that Fhit prevents spontaneous DSBs, specific small molecule inhibitors were used to inhibit each of these kinases individually in HEK293 cells, and comet assays were used to measure DNA breaks. The results shown in Fig. 4A show that Chk1 inhibition led to an increase in DSBs in control HEK293 cells. This increase was similar to the level of DNA breaks in untreated, Fhit-silenced HEK293 cells. In contrast, Chk1 inhibition in Fhit-

deficient HEK293 cells had little effect on DNA damage, suggesting that Fhit function to prevent DNA damage is dependent on Chk1 activity. ATR and ATM inhibitors were also used, however there was no dependency of Fhit function on either of these kinases (Fig. 4B and data not shown). Similarly, Chk1 inhibition led to an increase in DNA breaks in Fhit<sup>+/+</sup> mouse kidney cells, but caused no observable increase in damage in Fhit<sup>-/-</sup> mouse kidney cells (Fig. 4C). Because Fhit only suppresses DSBs when Chk1 activity is not inhibited, and Chk1 only suppresses DSBs in Fhit-expressing cells, we conclude that Fhit and Chk1 activities are co-dependent.

The observed co-dependency for Fhit and Chk1 is intriguing as Fhit and Chk1 appear to have some overlapping roles during S phase. For example, both Fhit and Chk1 promote fork progression during unperturbed S phase (Petermann et al., 2006; Saldivar et al., 2012); both prevent DNA damage during S phase (Gagou et al., 2010); and both prevent chromosome instability. Furthermore, the tumor spectrum in Chk1<sup>+/-</sup>Chk2<sup>-/-</sup> mice partially phenocopies that of Fhit<sup>-/-</sup> mice (Niida et al., 2010; Zanesi et al., 2001). It is not entirely clear how Chk1 promotes replication fork movement, but it is likely that Chk1 phosphorylates one or more proteins necessary for DNA replication. Of interest, Fhit has 2 motifs that are predicted to be phosphorylation targets of Chk1. Thus, a possible scenario to explain the co-dependency would be that Chk1 phosphorylates Fhit, leading to its activation to promote DNA replication. Inhibition of Chk1 kinase activity would lead to diminished Fhit function; in the absence of Fhit expression, Chk1 lacks its target to promote fork progression.

## Conclusion

There are a number of reports concerning suppression of tumorigenicity of xenografts after FHIT gene expression, numerous reports of exogenous expression causing apoptosis of recipient cells, and of FHIT gene therapy of xenografts; most of these studies showed that Fhit caused suppression or regression of tumors in preclinical models through apoptosis. We have shown that loss of expression of Fhit protein causes DNA damage and genome instability and expression of Fhit reduces this DNA damage and genome instability. In this report, we have further shown that these functions of Fhit are dependent upon the Fhit-substrate complex, as are other tumor suppressive functions of Fhit. However, it is clear that tumor suppression cannot occur through reduction of DNA damage in a recipient tumor cell because the DNA alterations have already occurred. Thus, it is likely that Fhit contributes to suppression of tumor initiation and progression through its role in protection of genome stability and that it has a second role in suppressing tumorigenicity through apoptosis, perhaps of cells that have sustained DNA damage. The finding that Fhit and Chk1 have co-dependent activities to minimize DNA damage suggests that loss of Fhit expression in the earliest preneoplastic lesions impairs one of the branches of the S phase checkpoint setting the stage for future tumorigenic events.

## Acknowledgments

We thank members of the Huebner lab for helpful discussions. This work was supported by grants from the National Institutes of Health, USPHS to KH (CA120516, CA132453, CA115965) and to JCS (F31CA157150, T32GM068412).

## References

1. Ahel I, Rass U, El-Khamisy SF, Katyal S, Clements PM, McKinnon PJ, et al. The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates. *Nature*. 2006; 443:713–716. [PubMed: 16964241]




2. Barnes LD, Garrison PN, Saprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5''-P1,P3-triphosphate hydrolase. *Biochemistry*. 1996; 35(36):11529–11535. [PubMed: 8794732]
3. Branzei D, Foiani M. The checkpoint response to replication stress. *DNA Repair (Amst)*. 2009; 8:1038–1046. [PubMed: 19482564]
4. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. *Nat Rev Mol Cell Biol*. 2008; 9:616–627. [PubMed: 18594563]
5. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation and disease. *The FASEB J*. 2003; 17:1195–1214.
6. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, et al. The genetic landscape of a cell. *Science*. 2010; 327:425–431. [PubMed: 20093466]
7. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. *Clin Cancer Res*. 2010; 16:376–383. [PubMed: 20068082]
8. Date H, Onodera O, Tanaka H, Iwabuchi K, Uekawa K, Igarashi S, et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. *Nat Genet*. 2001; 29:184–188. [PubMed: 11586299]
9. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature*. 2006; 444:638–642. [PubMed: 17136094]
10. Dumon KR, Ishii H, Fong LY, Zanasi N, Fianza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM. FHIT gene therapy prevents tumor development in Fhit-deficient mice. *Proc Natl Acad Sci U S A*. 2001; 98(6):3346–3351. [PubMed: 11248081]
11. Durkin SG, Glover TW. Chromosome fragile sites. *Annu Rev Genet*. 2007; 41:169–192. [PubMed: 17608616]
12. Durkin SG, Ragland RL, Arlt MF, Mülle JG, Warren ST, Glover TW. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. *Proc Natl Acad Sci U S A*. 2008; 105:246–251. [PubMed: 18162546]
13. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. *Mut Research*. 2004; 567:1–61.
14. Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX Phosphorylation, DNA Replication Fork Arrest, and Cell Death in the Absence of Chk1. *Mol Biol Cell*. 2010; 21:739–752. [PubMed: 20053681]
15. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature*. 2005; 434:907–913. [PubMed: 15829965]
16. Gueven N, Becherel OJ, Kijas AW, Chen P, Howe O, Rudolph JH, et al. Aprataxin, a novel protein that protects against genotoxic stress. *Hum Mol Genet*. 2004; 13:1081–1093. [PubMed: 15044383]
17. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, et al. Concordant loss of fragile gene expression early in breast cancer development. *Pathol Int*. 2005; 55:471–478. [PubMed: 15998374]
18. Guo Z, Kumagai A, Wang SX, Dunphy WG. Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in *Xenopus* egg extracts. *Genes Dev*. 2000; 14:2745–2756. [PubMed: 11069891]
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646–674. [PubMed: 21376230]
20. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, Croce CM. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. *Cancer Res*. 2001; 5(12):4059–4064.
21. Jayachandran G, Sazaki J, Nishizaki M, Xu K, Girard L, Minna JD, et al. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. *Cancer Res*. 2007; 67:10379–10388. [PubMed: 17974981]
22. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. *Cancer Res*. 1999; 59(14):3333–3339. [PubMed: 10416589]


23. Joannes A, Bonnomet A, Bindels S, Polette M, Gilles C, Bulet H, et al. Fhit regulates invasion of lung tumor cells. *Oncogene*. 2010; 29:1203–1213. [PubMed: 19935706]
24. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. *Nat Rev Mol Cell Biol*. 2008; 9:759–769. [PubMed: 18813293]
25. Li H, Balajee AS, Su T, Cen B, Hei TK, Weinstein IB. The HINT1 tumor suppressor regulates both gamma-H2AX and ATM in response to DNA damage. *J Cell Biol*. 2008; 183:253–265. [PubMed: 18852295]
26. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. *Genes Dev*. 2000; 14:1448–1459. [PubMed: 10859164]
27. Martin J, St-Pierre MV, Dufour JF. Hit proteins, mitochondria and cancer. *Biochim Biophys Acta*. 2011; 1807:626–632. [PubMed: 21316334]
28. Moreira MC, Barbot C, Tachi N, Kozuka N, Uchida E, Gibson T, et al. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. *Nat Genet*. 2001; 29:189–193. [PubMed: 11586300]
29. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. *Nat Rev Mol Cell Biol*. 2010; 11:220–228. [PubMed: 20177397]
30. Niida H, Murata K, Shimada M, Ogawa K, Ohta K, Suzuki K, et al. Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. *EMBO J*. 2010; 29:3558–3570. [PubMed: 20834228]
31. Okumura H, Ishii H, Pichiorri F, Croce CM, Mori M, Huebner K. Fragile gene product, Fhit, in oxidative and replicative stress responses. *Cancer Sci*. 2009; 100(7):1145–1150. [PubMed: 19486340]
32. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. *Mol Cell Biol*. 2006; 26:3319–3326. [PubMed: 16581803]
33. Pichiorri F, Palumbo T, Suh SS, Okamura H, Trapasso F, Ishii H, Huebner K, Croce CM. Fhit tumor suppressor: guardian of the preneoplastic genome. *Future Oncol*. 2008; 4(6):815–824. [PubMed: 19086848]
34. Pichiorri F, Okumura H, Nakamura T, Garrison PN, Gasparini P, Suh SS, Druck T, McCorkell KA, Barnes LD, Croce CM, Huebner K. Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions. *J Biol Chem*. 2009; 284(2): 1040–1049. [PubMed: 19004824]
35. Rimessi A, Marchi S, Fotino C, Romagnoli A, Huebner K, Croce CM, Pinton P, Rizzuto R. Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. *Proc Natl Acad Sci U S A*. 2009; 106(31):12753–12758. [PubMed: 19622739]
36. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. *Proc Natl Acad Sci U S A*. 2002; 99(6):3615–3620. [PubMed: 11891319]
37. Saldivar JC, Shibata H, Huebner K. Pathology and biology associated with the fragile FHIT gene and gene product. *J Cell Biochem*. 2010
38. Saldivar JC, Miuma S, Bene J, Hosseini SA, Shibata H, Sun J, Wheeler LJ, Mathews CK, Huebner K. Initiation of genome instability and preneoplastic processes through loss of Fhit expression. *PLoS Genet*. 2012 In press.
39. Sano Y, Date H, Igarashi S, Onodera O, Oyake M, Takahashi T, et al. Aprataxin, the causative protein for EAOH is a nuclear protein with a potential role as a DNA repair protein. *Ann Neurol*. 2004; 55:241–249. [PubMed: 14755728]
40. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. *Cancer Res*. 2003; 63:1183–1187. [PubMed: 12649173]
41. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. *Proc Natl Acad Sci U S A*. 1997; 94(25):13771–13776. [PubMed: 9391102]

42. Sung HJ, Ma W, Wang PY, Hynes J, O’Riordan TC, Combs CA, et al. Mitochondrial respiration protects against oxygen-associated DNA damage. *Nat Commun.* 2010; 1:5. [PubMed: 20975668]
43. Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. *J Biol Chem.* 2008; 283(20):13736–13744. [PubMed: 18319262]
44. Trapasso F, Krakowiak A, Cesari R, Arkles J, Yendamuri S, Ishii H, Vecchione A, Kuroki T, Bieganski P, Pace HC, Huebner K, Croce CM, Brenner C. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. *Proc Natl Acad Sci U S A.* 2003; 100(4):1592–1597. [PubMed: 12574506]
45. Tsantoulis PK, Kotsinas A, Sfrikakis PP, Evangelou K, Sideridou M, Levy B, et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. *Oncogene.* 2008; 27:3256–3264. [PubMed: 18084328]
46. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, et al. The tumor spectrum in FHIT-deficient mice. *Proc Natl Acad Sci U S A.* 2001; 98:10250–10255. [PubMed: 11517343]







**Fig. 1.** Examples of chromosome aberrations in *Fhit*-deficient cells. A. Representative images of sister chromatid exchanges (SCEs) in *Fhit*<sup>+/+</sup> and *Fhit*<sup>-/-</sup> mouse epithelial cells. On average, *Fhit*<sup>-/-</sup> cells have more than twice as many SCEs/metaphase than *Fhit*<sup>+/+</sup> cells. B. Representative karyotype image of *Fhit*<sup>+/+</sup> and *Fhit*<sup>-/-</sup> mouse epithelial cells illustrating an abnormal chromosome number in *Fhit*-negative cells.



**Fig. 2.** The Fhit-substrate complex suppresses DNA breaks. **A.** Western blots of Fhit and GAPDH expression in H1299 cancer cells 3 days after transient transfection with pRcCMV-FHIT-wt (wt), pRcCMV-empty vector (ev), pRcCMV-FHIT-H96N mutant (H96N), pRcCMV-FHIT-Y114A mutant (Y114A), or pRcCMV-FHIT-Y114F mutant (Y114F). **B.** Immunofluorescence of Fhit expression in H1299 cells transfected as in (A); bars, 20  $\mu$ m. **C.** Transfection efficiency of H1299 cells transfected as in (A). Transfection efficiencies were determined as (Fhit-expressing cells/total cells) $\times$ (100%) using immunofluorescence images obtained as in (B). **D.** Neutral comet assays and box plots of tail moments of H1299 cells transfected as in (A). Statistical significance was determined using the Kruskal-Wallis rank sum test; \* $P < 0.005$  for each comparison.



**Fig. 3.** DNA damage in Fhit-deficient cells is not caused by oxidative stress. A. Neutral comet assays and box plots of tail moments of Fhit<sup>+/+</sup> and Fhit<sup>-/-</sup> mouse kidney epithelial cells treated with N-acetyl-L-cysteine (NAC), 3 mM for 40 h, or mock treated. B. Neutral comet assays and box plots of tail moments of Fhit<sup>+/+</sup> and Fhit<sup>-/-</sup> mouse kidney cells grown in an ambient atmospheric environment (20% oxygen) or in a low oxygen environment (5% oxygen).



**Fig. 4.** Fhit function is dependent upon Chk1 activity. A and B. Neutral comet assays and box plots of tail moments of control or FHIT-silenced HEK293 cells treated for 4 h with a Chk1 inhibitor (A) or an ATR inhibitor (B). C. Neutral comet assays and box plots of tail moments of Fhit<sup>+/+</sup> and Fhit<sup>-/-</sup> mouse kidney cells treated for 4 h with a Chk1 inhibitor. P-values were calculated using the Kruskal-Wallis rank sum test.